Introduction
============

Ovarian cancer (OC) accounts for about 2.5% of total malignancies among women, however, causing nearly 5% of all cancer-related deaths due to its high mortality rate [@B1]-[@B3]. In the year of 2018, there are approximately 22,240 newly diagnosed ovary cancer cases, and about 14,070 estimated deaths occurred [@B2]. OC patients were often found at an advanced stage (III or IV) when diagnosed, taking up over 60% of the total number, with synchronous distant metastases [@B4]. That might partially explain their higher mortality [@B5]. According to the latest study, the brain ranked the fifth common metastatic site behind the liver, distant lymph nodes, lung, and bone [@B6]. Brain metastases from ovary cancer always portend a grave prognosis, leaving only a few months of survival after diagnosis [@B7]. The incidence of ovarian carcinoma with brain metastases (OCBM) was reported to range from 0.29% to 12.0 %[@B8]-[@B13].

However, clinical data on ovarian cancer brain lesions are scarce. The scarcity and low prevalence of OCBM make it challenging to draw firm conclusions or reach a consensus on the optimal therapy. Moreover, the brain remains a "sanctuary site" for the complex blood-brain barrier structure, limiting the penetration of drugs and causing problems for treatment. Treatment strategies are still controversial, and their efficiency needs further evaluation. Besides, there are still many things unknown about the predictors as well as prognostic factors of OCBM. There is a lack of reliable and multicentral population-based series study of the incidence of brain metastases in ovary cancer diagnosis [@B14]. Based on the SEER database, this article focused on the risk and prognostic factors of de novo brain metastases in ovarian carcinoma.

Materials and Methods
=====================

Database
--------

The SEER database has recorded cancer data of 18 population-based cancer registries, covering nearly 30% of the U.S. population [@B15], [@B16]. It has collected information on patient clinical demographics, primary tumor site, tumor morphology and stage at diagnosis, the first course of therapy, and follow-up for vital status (<https://seer.cancer.gov/about/overview.html>). We employed the SEERStat software to determine eligible patients for analysis, and extracted the information on cancer incidence from the official website (<https://seer.cancer.gov/>). Since the SEER database began to record metastatic information including brain metastases from the year of 2010. We collected the information about OCBM from 1 January 2010 to 31 December 2016.

Study population
----------------

In the SEER database, a total of 40,860 patients were diagnosed with ovarian cancer, excluding 395 less than 18 years old. Among them, we identified 38,021 patients with clear brain metastasis information. We excluded those patients with other cancers, or unknown sequence numbers, or diagnosed by autopsy or via death from the analysis, leaving 29,512 active follow-up patients in the final cohort for further analysis. Of these, 3546 patients diagnosed with metastatic disease to any distant site, and 89 patients diagnosed with OCBM.

In the entire cohort, the percentage of metastatic disease was 12.02%, and the brain metastasis was 0.30%. The data extraction flowchart was shown in Figure [1](#F1){ref-type="fig"}. The inclusion criteria were as follows: age elder than 18 years old; ovary cancer as the only primary malignant tumor; with clear information on brain metastases; with active follow-up. Exclusion criteria included the following requirements: age younger than 18 years old at diagnosis; with cancer other than ovary cancer; no clear information about brain metastases; diagnosis based on the death certificate or autopsy; no definite survival time; no active follow-up.

Statistical analysis
--------------------

The baseline characteristics of the population were shown in Table [1](#T1){ref-type="table"}. We stratified the patients by age (18-58, 59+ years old), race (white, black, others and unknown), origin recode (Spanish-Hispanic-Latino and Non-Spanish-Hispanic-Latino), laterality (unilateral including left, right, only one side unspecified, bilateral and unknown), sequence of radiotherapy and surgery (radiotherapy before surgery, radiotherapy after surgery, radiotherapy before and after surgery and others), treatment and other sociodemographic information, such as marital status (married, single, divorced, widowed and unknown), insurance situation (yes, no and unknown), residence type (rural, urban, metropolitan and unknown). Based upon the 7th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, we classified T staging (T1, T2, T3 and unknown) and N staging (N0, N1 and unknown). Tumor staging was classified into 5 categories: I, II, III, IV and unknown, according to the 7^th^ edition of the AJCC Cancer Staging Manual and SEER combined stage group as well. Surgery was classified as unilateral/bilateral (salpingo-) oophorectomy (25-28, 35-37, 50-52, 55-57, 80); debulking/cytoreductive surgery (60-63), others (17, 70-74, 90) and no surgery (0, 99). We reclassified treatment into 8 categories: patients receiving all three therapeutic approaches including chemotherapy, surgery and radiotherapy(CSR), radiotherapy and surgery (RS), chemotherapy and surgery (SC), radiotherapy and chemotherapy (RC), only receiving radiotherapy (R), only receiving surgery (S), only receiving chemotherapy(C) and patients received none of any treatment above (Others) as other investigators[@B16]. We defined the resident type by the county attributes from the 2003 US Department of Agriculture rural-urban continuum codes.

We stratified baseline clinical data (Table [1](#T1){ref-type="table"}) and calculated the incidence proportion of the OCBM patients among the metastatic disease cohort and the entire cohort as well. Besides, we employed univariable and multivariable logistic regression analysis to identify potential predictors for the incidence of brain metastases at the diagnosis of OC. Survival estimates were based on the Kaplan-Meier method. Univariate and multivariate Cox regression analysis were employed to identify potential covariates associated with increased all-cause mortality. In the Cox regression model, we constructed 2 models for analysis. The first model included the following variables: marital status, histology, surgery, radiotherapy, chemotherapy, and insurance type. In the second model, we used treatment (CSR, RS, SC, RC, R, S, C, Others) to replace three therapeutic variables (surgery, radiotherapy, chemotherapy), and keep other variables the same with the model 1, as other investigators[@B16].

Additionally, to further control the potential confounding factors across groups, we employed a 1:1 propensity-score matching (PSM) analysis based on whether brain met or not to re-examine the impact of brain metastasis among ovarian cancer on the overall survival. In this study, a 1:1 pair matching was performed by the nearest neighbor method to generate a matched pair among the brain met group and without brain met group. A chi-square test was employed to compare categorical variables across groups.

The statistical analyses were performed using SPSS statistical software (version 22.0) and RStutio (version 1.1.453). A two-sided *p*-value \< 0.05 was considered statistically significant.

Results
=======

Patient characteristics and Proportion
--------------------------------------

A total of 29,512 patients diagnosed with ovary cancer entered into our study, including 89 patients diagnosed with OCBM, and the median age was 62. The clinical baseline characteristics were demonstrated in Table [1](#T1){ref-type="table"}. Among 29,512 patients diagnosed with ovary cancer between 2010 and 2016 in the U.S., 3546 (12.02%) presented with metastatic disease, and 89 (0.30%) patients presented with synchronous brain metastases when diagnosed.

According to the univariable logistic regression in the entire cohort [Table S1](#SM0){ref-type="supplementary-material"}, fourteen factors achieved significance (p \<0.05), including age, laterality, histology, T, N, surgery, radiotherapy, chemotherapy, radiation sequence with surgery, the presence of bone, lung and liver metastasis, CA125, and insurance type. As is shown in Table [1](#T1){ref-type="table"}, the elder age (0.36%) was prone to presenting brain metastases than younger age (0.23%) (P\<0.05), the unknown laterality (0.72%) was more likely to be OCBM than unilateral laterality (0.42%, P\<0.0001), the tumor staging grade IV (1.06%), and unspecified (0.09%) got more risk of OCBM compared to grade III (0.01%, P\<0.0001, respectively), unknown N staging (0.75%) was more likely to develop OCBM than N0 (0.22%, P\<0.0001) among the entire cohort. For histology, unspecified (2.02% and 8.37%) had a higher proportion of brain metastasis than epithelial neoplasms (0.25% and 2.21%) (P\<0.0001). In the treatment, the absence of chemotherapy (0.53% and 4.27%) had a significantly higher likelihood of developing brain metastasis than chemotherapy treatment (0.20% and 1.69%) (P\<0.0001). Besides, the brain metastases rate of uninsured patients (0.64%) was higher than insured patients (0.28%) (P\<0.001) among the entire cohort, which might due to the patients with insurance might suffer less risk to develop metastatic diseases for they could receive more medical intervention.

We then put these factors into multivariable logistic regression and found that laterality, histology, surgery, radiotherapy, chemotherapy, bone met, liver met and lung met had significance among the entire cohort and histology, radiotherapy, chemotherapy, bone met, liver met and lung met achieved significance among the subset with metastatic disease cohort. According to the multivariable logistic regression based on the entire cohort (Table [2](#T2){ref-type="table"}), laterality (bilateral vs unilateral, OR, 2.251; 95%CI, 1.206-4.204; P=0.011), unspecified histology (vs epithelia neoplasms; OR, 2.568; 95%CI, 1.246-5.293; P=0.011); surgery no surgery (vs U/BSO; OR, 4.047, 95%CI, 1.702-9.624; P=0.002); radiotherapy (vs no radiotherapy; OR, 32.268; 95%CI, 15.423-67.508; P\<0.0001) and chemotherapy (vs no chemotherapy; OR, 0.503; 95%CI, 0.287-0.881; P=0.016), bone met (vs no bone met; OR, 5.095; 95%CI, 2.737-9.488; P\<0.0001) and unknown (vs no bone met; OR, 7.271; 95%CI, 1.811-29.190; P=0.005), liver met (vs no liver met; OR, 1.072; 95%CI, 0.581-1.977; P\>0.05) and unknown (vs no liver met; OR, 5.266; 95%CI, 1.706-16.250; P=0.004) , lung met (vs no lung met; OR, 5.328; 95%CI, 3.124-9.085; P\<0.0001) and unknown (vs no lung met; OR, 1.627; 95%CI, 0.369-7.176; P=0.521). The multivariable logistic regression results of the subset with metastatic disease were also presented in Table [2](#T2){ref-type="table"}.

Survival
--------

The univariate analysis of all-cause mortality among the entire cohort as well as the subset with brain metastases were presented in [Table S2](#SM0){ref-type="supplementary-material"}. Seven factors were significantly associated with overall survival among brain metastases subset (p \<0.05). They were marital status, histology, treatment, surgery, radiotherapy, chemotherapy, and insurance situation. On Cox regression analysis among brain metastases in the model 1, the results (Table [3](#T3){ref-type="table"}) showed that divorced (vs married; HR, 2.688, 95%CI, 1.102-6.560; P=0.030), no surgery (vs U/BSO; HR, 3.712, 95%CI, 1.519-9.075; P=0.004) were significantly associated with increased all-cause mortality and chemotherapy (vs no chemotherapy; HR, 0.341, 95%CI, 0.169-0.687; P=0.003) reduced the risk of death. While single marital status (vs married; HR, 0.679, 95%CI, 0.351-1.313; P=0.249) and cytoreductive surgery (vs U/BSO; HR, 1.042, 95%CI, 0.317-3.421; P\>0.05) didn\'t achieve any statistical difference in OS in model 1. Moreover, marital status and treatment significantly correlated with all-cause mortality in model 2 (Table [3](#T3){ref-type="table"}). Marital status divorced (vs married; HR, 2.672, 95%CI, 1.027-6.953; P=0.044) and treatment were significantly associated with increased all-cause mortality. Intriguingly, being divorced was associated with a higher risk of mortality than married status, while single (vs married; HR, 0.643, 95%CI, 0.327-1.264; P=0.200) was not statistical significant. And treatment chemotherapy+surgery+radiotherapy (vs others; HR, 0.096, 95%CI, 0.030-0.308; P\<0.0001), surgery plus chemotherapy (vs others; HR, 0.081, 95%CI, 0.021-0.312; P\<0.0001), radiotherapy plus chemotherapy (vs others; HR, 0.260, 95%CI, 0.115-0.587; P=0.001) were found to be protective interventions of survival in model 2. Generally, it seemed that divorced marital status, absence of positive treatment including any combination with surgery, chemotherapy, and radiotherapy had increased risk of mortality among OCBM patients.

The median survival time of the OCBM cohort was 2.0 months (IQR: 0.0-10.0mo) (Table [1](#T1){ref-type="table"}, Figure [2](#F2){ref-type="fig"}A). The median survival time for the patients with unilateral/bilateral (salpingo-) oophorectomy was 12.0 months (7.5-30.75mo), with cytoreductive surgery was 12.0 months (IQR: 2.0-35.5 mo), without surgery was 2.0 months (IQR: 0.0-4.0 mo) (Figure [3](#F3){ref-type="fig"}A). Median survival time of patients receiving chemotherapy was 9.0 months (IQR: 2.0-16.0 mo), while no chemotherapy was 1.0 month (IQR: 0.0-2.0mo) (Figure [3](#F3){ref-type="fig"}B). The median survival time for radiation-treated patients was 4.0 months (IQR: 2.0-12.0mo), among those without radiation was 1.5 months (IQR: 0.0-6.0 mo) (Figure [3](#F3){ref-type="fig"}C).

Median survival time among the sequence of radiotherapy and surgery indicated those received radiotherapies before surgery were 9.0 months (NA mo), radiation after surgery was 10.0 months (IQR: 2.0-14.0 mo), others were 2.0 months (IQR: 0.0-6.0 mo) (Figure [3](#F3){ref-type="fig"}D). Median survival time of CSR-treated patients was 12.0 months (IQR: 5.5-39.0mo), RS-treated was 2.0 months (IQR: 2.0-NA mo), SC-treated was 20.0 months (IQR:18.0-56.5mo), RC-treated was 4.0 months (IQR: 2.0-10.0mo), R-treated was 0.5 months (IQR: 0.0-2.5mo), S-treated was 4.5 months (IQR: 3.0-NAmo), C-treated was 3.0 months (IQR: 0.25-7.0mo), others was 0.0 month (IQR:0.0-2.0mo) (Figure [4](#F4){ref-type="fig"}). Survival analysis among the number of extracranial metastases was displayed in [Figure S1](#SM0){ref-type="supplementary-material"} as supplementary.

Survival analysis among PSM-matched cohort
------------------------------------------

Given the confounding factors between groups of with or without brain metastases, a 1:1 ratio PSM was used to balance the baseline clinical characteristics. There was no variable that achieved significant difference between case and controls (Table [4](#T4){ref-type="table"}) after matching. In the matched cohort, we included 178 OC patients: 89 cases of brain met group and another 89 cases of without brain met group. Based upon the comparable variables between two groups, we conducted univariate Cox regression to draw a more accurate conclusion: ovary cancer with brain metastases contributed to poor prognosis for OC patients (Figure [1](#F1){ref-type="fig"}B, P\<0.05). The median survival time of with or without brain metastases group was 2.0 months (IQR: 0.0-9.0 mo) and 5.0 months (IQR: 1.0-14.3 mo), respectively. 1:1 PSM based multivariate Cox regression identified 2 new factors (brain met and liver met), apart from the above prognostic factors for OS (Table [5](#T5){ref-type="table"}).

We found that the presence of brain metastases at newly diagnosed ovarian cancer associated with shorter survival time compared with the propensity-score-matched control group in our study (Figure [1](#F1){ref-type="fig"}B). Also, the result indicated that patients receiving aggressive therapy benefited more in survival. The prognosis of patients treated with SC was best, while patients received other treatments had a poorer prognosis.

Discussion
==========

This study described the incidence and survival of the ovarian carcinoma patients with brain metastases at intial diagnosis based on the SEER database. The present study was the first time investigating both predictors and prognostic factors of de novo OCBM. Noteworthily, this population-based study also firstly employed the PSM analysis method to evaluate the role of brain metastases in ovarian carcinoma. BM was considered to be a rare and late event in ovarian carcinoma [@B3], it usually followed with high mortality, poor prognosis, causing colossal health burden and expensive medical costs [@B17]. Although several systematic reviews and articles had been published upon the topic of ovarian cancer brain metastases [@B1], [@B3], [@B14], [@B18], sufficient evidence had not been found to provide clear guidelines on proper treatment, let alone the de novo brain metastases of ovarian carcinoma. In this circumstance, early detection and comprehensive treatment were of great significance, for it may alter the natural progression and improve overall survival. Thus, it is necessary to study OCBM patients in a large-scale cohort.

We found that 0.30% of patients with brain metastases at initial diagnosis of ovary cancer, and 12.02% was with metastatic disease at diagnosis, which were similar to previous study[@B19], and a little lower than some researches [@B6], [@B7], [@B10], [@B17], [@B20]-[@B22]. This may be because they counted not only patients with brain metastases at the time of diagnosis of ovarian cancer, but also patients with subsequent brain metastases. We identified predictors of OCBM using multivariate logistic regression. This study found that the unspecified histology, absence of surgery, no chemotherapy, and more extracranial metastasis sites increased the risk of developing OCBM in the entire cohort, which was similar to previous studies [@B8], [@B14], [@B18], [@B20], [@B23]-[@B25]. However, Cohen et al. [@B10] held the opposite view that there was no association between the BM and the presence of other extracranial metastases.

Moreover, we also found that patients with bilateral laterality were more likely to be OCBM, which had never been reported before as we knew. Intriguingly, radiotherapy was found to be a higher risk of metastatic diseases to any site, including brain metastases, which might due to the fact that OCBM patients are usually in advanced disease when receiving radiation therapy as palliative treatment. However, only surgery and chemotherapy treatment had a lower risk to be OCBM, and our study did not show that positive or negative of CA125 elevation associated with OCBM, which were consistent to the research published before[@B18], [@B26], however, was different with Divine et al. [@B25]. These researches [@B1], [@B8], [@B27] showed that elder age, residence type and ethnicity were the risk factors for brain metastases, but in our study, these variables only achieved significance on the univariate logistic analysis.

This study indicated that bilateral laterality, unspecified histology, absence of surgery or chemotherapy, more extracranial metastasis might suffer a higher likelihood to be brain metastases among OC patients. Thus, these high-risk people might require a further examination at the initial diagnosis. Besides, patients without insurance should be encouraged to get screening regularly.

Furthermore, we found that divorced marriage, absence of surgery, absence of chemotherapy, and no insurance harmed overall survival among OCBM upon multivariate logistic regression analysis. And histology, radiotherapy and insurance status were not associated with prognosis which were similar to the previous study [@B28]-[@B30]. We supposed that divorced patients went through more sufferings during the failed marriage, getting less treatment due to lacking their spouses\' support, leading to poor survival. However, the unmarried status like single and widowed did not achieve statistical significance in overall survival in this study, which differed from the previous research. The extracranial metastases sites which showed decreased survivals had been reported [@B10], [@B15], [@B31], while in our study, extracranial metastases showed poorer survival among the entire cohort, but not in the OCBM subset. However, the reason remains unknown which needs further exploration.

To obtain satisfactory cytoreductive surgery and sensitive chemotherapy are the common treatment strategy for ovarian cancer [@B32], [@B33], which also applies to OCBM patients in this study. Surgery, radiation, and chemotherapy are the major treatment methods to prolong the patients\' survival. Mostly, surgery supplemented with radiation therapy is a common choice. In our study, chemotherapy was the most common treatment in 89 patients (46.1%), which is slightly different from the previous research, for these had radiotherapy as the mostly used treatment [@B24]. However, it is still controversial on the effect of chemotherapy for many chemotherapeutic drugs that cannot permeate the blood-brain barrier (BBB), which drastically limits the effectiveness. And some concerns that the use of systemic chemotherapy may corrupt the BBB. Thus, radiotherapy remains top choice for OC treatment, except for the brain metastases, which in turn helps to explain the former difference. There are two types of radiotherapy, which are commonly used, including stereotactic radiosurgery (SRS) and whole-brain radiotherapy (WBRT). Some authors [@B24], [@B34] reported that WBRT could cause physical and cognitive decline. A systemic retrospective study [@B35] confirmed that SRS had a better effect on the treatment of OCBM, with more adequately measured lesions, less-lethal of healthy cells as well as less adverse responses, compared to the WBRT. Besides, recent studies have shown that systemic chemotherapy for brain metastases showed favorable responses and prolonging their survival [@B6], [@B17], [@B18].

In model 1, the median survival time of OCBM patients decreased 2.5 months from chemotherapy to no chemotherapy (P\<0.001). Moreover, median survival time decreased 10 months from U/BSO surgery to no surgery (P\<0.001) and the prognosis for U/BSO surgery looks similar to the cytoreductive surgery (P\>0.05). The median survival time from no radiotherapy to radiotherapy increased by 2.5 months (P\<0.001). Besides, compared with surgery only (4.5 mo) (P\>0.05) or chemotherapy only (3.0 mo) (P=0.031), patients who acquired surgery plus chemotherapy seemed to have longer median survival (20 mo). In model 2, median survival time of OCBM patients increased 12 months from others to RSC, 2 months from others to RS, decreased 20 months from SC to others, 3 months from C to others (P\>0.05), 4.5 months from S to others (P\>0.05), and there was little difference from others to RS or R. This result indicated that patients receiving multimodal therapy had significant benefits on survival. According to the results above, OCBM patients benefit more from chemotherapy and surgery, especially a combination of two, but radiotherapy achieved no statistical significance in overall survival analysis. The median survival of SC was the best, while patients with "others" treatment had the worst prognosis. The present study showed SC had the best prognosis, followed by CSR and RC among the comprehensive treatments for OCBM, but RS showed no statistical difference for overall survival, which might be meaningful for clinical practice. What\'s more, we found similar results in our PSM-matched analysis: in model 1, divorced marital status, absence of treatment including surgery and chemotherapy, liver met, and lung met were associated with more reduced overall survival among OCBM patients. Likewise, in model 2, single, divorced marital status showed poor prognosis, and combined treatment including CSR, SC, and RT was significantly associated with improved OS. Surgery or chemotherapy could also considerably reduce the risk of OCBM death. However, radiotherapy did not show statistical significance in improving the overall survival among OCBM patients based on the PSM-matched analysis.

Limitations
-----------

Although this study is the large-scale multi-center study, but it has some limitations. Firstly, we only know the information of four metastatic sites, including the liver, bone, lung, and brain. This database has not included information on other metastatic sites, such as peritoneal metastases. Besides, we only knew the information of synchronous metastasis to the brain, consisting of a small part regarding those who might develop metachronous metastasis afterward. Secondly, some well-established covariates of survival such as comorbidities or performance status or even some tumor-related data such as stage, the types and numbers of brain metastases, the size of tumor, mammography screening, and treatment for comorbidities are not available in the database. Thirdly, the SEER database has not recorded the morbidity and mortality after treatment. Lastly, residence type was labeled at a county level, rather than a patient level, which may affect the results of the analysis.

This study firstly conducted a population-based analysis of OCBM patients as well as PSM-based analysis, to our knowledge. It provided valuable advice for patients with higher risk of OCBM to consider using MRI assessment. Besides, we also analyzed the prognostic factors of OCBM in the research. Additionally, the study compared the significance of different therapies for OCBM patients and provided recommendations for their clinical treatment. Moreover, this large-scale study used an efficient statistical method to emphasize the reliability of the impact of de novo brain metastases on survival in patients with OC.
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###### 

Clinical Characteristics of Patients for Ovarian Cancer Patients Diagnosed with and without Brain Metastases

  Variables                                Patients, No.   Proportion of Brain Metastases, %   Survival among Patients with Brain Metastases, Median (IQR), mo                   
  ---------------------------------------- --------------- ----------------------------------- ----------------------------------------------------------------- ------- ------- ---------------
  **Age (years)**                                                                                                                                                                
  Median (range)                           62 (18-102)     \-                                  \--                                                                               
  18-58                                    12359           28                                  12331                                                             0.23    2.72    3(2-11.25)
  ≥59                                      17153           61                                  17092                                                             0.36    2.42    2 (0-10)
  **Marital status**                                                                                                                                                             
  Married                                  14188           35                                  14153                                                             0.25    2.26    3(1-12)
  Single                                   6565            22                                  6542                                                              0.34    2.77    2(0-10.5)
  Divorced                                 2990            8                                   2982                                                              0.27    2.18    1 (0-2)
  Widowed                                  4424            17                                  4408                                                              0.38    2.51    2(0-7)
  Unknown                                  1345            7                                   1338                                                              0.52    4.38    4(2-10)
  **Race**                                                                                                                                                                       
  White                                    23792           70                                  23722                                                             0.29    2.50    2(0-9)
  Black                                    2692            12                                  2692                                                              0.45    2.64    2(0.25-36)
  Others                                   2852            5                                   2847                                                              0.18    1.75    2(0-18.5)
  Unknown                                  176             2                                   174                                                               1.14    22.22   10.5(NA)
  **Origin recode**                                                                                                                                                              
  Hispanic                                 4136            11                                  4125                                                              0.27    2.43    6(2-12)
  None-hispanic                            25376           78                                  25298                                                             0.31    2.52    2(0-10)
  **Laterality**                                                                                                                                                                 
  Unilateral                               15441           32                                  15409                                                             0.42    1.51    
  Bilateral                                9362            23                                  9339                                                              0.25    1.24    6(2-15)
  Unknown                                  4709            34                                  4675                                                              0.72    2.05    1.5(0-6.25)
  **Tumor staging**                                                                                                                                                              
  I                                        6966            0                                   6966                                                              0       0       NA-
  II                                       2435            0                                   2435                                                              0       0       NA
  III                                      10799           1                                   10798                                                             0.01    33.33   6(NA)
  IV                                       8239            87                                  8152                                                              1.06    2.47    2(0-10)
  Unknown                                  1073            1                                   1072                                                              0.09    4.76    2(NA)
  **T staging**                                                                                                                                                                  
  T1                                       7811            11                                  7800                                                              0.14    6.55    2(0-12)
  T2                                       3724            9                                   3265                                                              0.24    3.01    4(1-12.5)
  T3                                       15084           26                                  15058                                                             0.17    1.22    5(2-12.75)
  Unknown                                  2893            43                                  2850                                                              1.49    4.57    2(0-6)
  **N staging**                                                                                                                                                                  
  N0                                       20246           45                                  20201                                                             0.22    2.73    2(0-12.5)
  N1                                       6202            21                                  6181                                                              0.34    1.91    2(0.5-9)
  Unknown                                  3064            23                                  3041                                                              0.75    2.89    3(1-7)
  **Histology**                                                                                                                                                                  
  Epithelial neoplasms                     26303           67                                  26236                                                             0.25    2.12    2(1-10)
  Gonadal neoplasms                        1297            2                                   1295                                                              0.15    5.00    21.5(12-NA)
  Others                                   1071            3                                   1068                                                              0.28    2.07    12(2-NA)
  Unknown                                  841             17                                  824                                                               2.02    8.37    0(0-2.5)
  **Treatment^a^**                                                                                                                                                               
  Others                                   3371            37                                  3334                                                              1.10    3.98    0(0-2)
  CSR                                      213             13                                  200                                                               6.10    29.55   12(5.5-39)
  RS                                       24              3                                   21                                                                12.50   60.00   2(2-NA)
  SC                                       17127           5                                   17122                                                             0.03    0.35    20(18-56.5)
  RC                                       77              15                                  62                                                                19.48   31.25   4(2-10)
  R                                        38              6                                   32                                                                15.79   30.00   0.5(0-2.5)
  S                                        5647            2                                   5645                                                              0.04    1.18    4.5(3-NA)
  C                                        3015            8                                   3007                                                              0.27    0.90    3(0.25-7)
  **Surgery**                                                                                                                                                                    
  U/BSO                                    12146           14                                  12132                                                             0.12    2.77    12(7.5-30.75)
  Cytoreductive                            10360           9                                   10351                                                             0.09    0.83    12(2-35.5)
  Others                                   505             0                                   505                                                               0       0       NA
  No                                       6501            66                                  6435                                                              1.02    3.50    2(0-4)
  **Radiotherapy**                                                                                                                                                               
  No                                       29160           52                                  29108                                                             0.18    1.52    1.5 (0-6)
  Yes                                      352             37                                  315                                                               10.51   31.62   4(2-12)
  **Chemotherapy**                                                                                                                                                               
  No                                       9080            48                                  9032                                                              0.53    4.27    1(0-2)
  Yes                                      20432           41                                  20391                                                             0.20    1.69    9(2-16)
  **Radiation Sequence with surgery^b^**                                                                                                                                         
  RBS                                      15              1                                   14                                                                6.67    14.29   9(NA)
  RAS                                      235             17                                  218                                                               7.23    35.42   10(2-14)
  RBAS                                     1               0                                   1                                                                 0       0       NA
  Others                                   29261           71                                  29190                                                             0.24    2.03    2(0-6)
  **Bone Met**                                                                                                                                                                   
  No                                       29160           61                                  29099                                                             0.21    1.90    2(0-11)
  Yes                                      310             24                                  286                                                               7.74    7.74    3(0-8.5)
  Unknown                                  42              4                                   38                                                                9.52    18.18   2.5(0.5-9.75)
  **Liver Met**                                                                                                                                                                  
  No                                       27249           62                                  27187                                                             0.23    4.47    2(0-10.5)
  Yes                                      2120            21                                  2099                                                              0.99    0.99    2(0.5-5)
  Unknown                                  143             6                                   137                                                               4.20    15.00   2(0-12.75)
  **Lung Met**                                                                                                                                                                   
  No                                       27538           49                                  27489                                                             0.18    2.85    2(0.5-11)
  Yes                                      1773            37                                  1736                                                              2.09    2.09    2(0-8)
  Unknown                                  201             3                                   198                                                               1.49    5.36    0(NA)
  **CA125**                                                                                                                                                                      
  Normal                                   2654            4                                   2650                                                              0.15    5.13    16.5(6-54.75)
  Elevated                                 20241           49                                  20192                                                             0.24    1.80    2(0-8)
  Unknown                                  6617            36                                  6581                                                              0.54    4.85    2(0-11.5)
  **Insurance situation**                                                                                                                                                        
  No                                       1096            7                                   1089                                                              0.64    4.55    2(0-2)
  Yes                                      27927           77                                  27846                                                             0.28    2.31    2(0-12)
  Unknown                                  489             5                                   484                                                               1.02    8.33    3(2.5-6.5)
  **Residence type**                                                                                                                                                             
  Rural                                    482             1                                   481                                                               0.21    1.67    2(NA)
  Urban                                    3376            12                                  3364                                                              0.36    3.10    1(0-2.75)
  Metropolitan                             25630           76                                  25554                                                             0.30    2.46    2.5(0.25-12)
  Unknown                                  24              0                                   24                                                                0       0       NA

Abbreviations: OC: ovary cancer; IQR: interquartile range; CI: confidence interval.

^a^ including CSR: chemotherapy, surgery, and radiotherapy, RS: radiotherapy and surgery, SC: surgery and chemotherapy, RC: radiotherapy and chemotherapy, R: radiotherapy alone, S: surgery alone, C: chemotherapy alone, others: other treatment except for radiotherapy, surgery, and chemotherapy.

^b^including RBS: radiation before surgery, RAS: radiotherapy after surgery, RBAS: radiotherapy before and after surgery, others: without surgery or radiotherapy or unknown sequence.

###### 

Multivariate Logistic Regression for the Patients with Brain Metastases at Diagnosis of Ovary Cancer

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                             Patients, No   Among Entire\   Among Subset with Metastatic Disease                                                               
                                                       Cohort                                                                                                             
  ------------------------------------- -------------- --------------- -------------------------------------- ------------------------ ---------- ----------------------- ----------
  **Age (years)**                                                                                                                                                         

  18-58                                 12359          1028            28                                     Reference                           Reference               

  ≥59                                   17153          2518            61                                     1.331(0.760-2.329)       0.317      0.742(0.412-1.337)      0.321

  **Laterality**                                                                                                                                                          

  Unilateral                            15441          1192            32                                     Reference                           Reference               

  Bilateral                             9362           1130            23                                     2.251(1.206 -4.204)      0.011      1.649(0.831-3.270)      0.152

  Unknown                               4709           1224            34                                     0.742(0.403-1.366)       0.338      0.564(0.298-1.067)      0.078

  **T staging**                                                                                                                                                           

  T1                                    7811           168             11                                     Reference                           Reference               

  T2                                    3724           299             9                                      0.607(0.225-1.636)       0.324      0.466(0.151-1.444)      0.186

  T3                                    15084          2138            26                                     0.706(0.301-1.657)       0.424      0.455(0.179-1.152)      0.097

  Unknown                               2893           942             43                                     1.555(0.645-3.750)       0.325      0.826(0.335-2.037)      0.679

  **N staging**                                                                                                                                                           

  N0                                    20246          1650            45                                     Reference                           Reference               

  N1                                    6202           1101            21                                     0.689(0.371-1.279)       0.238      0.837(0.452-1.551)      0.571

  Unknown                               3064           795             23                                     0.678(0.364-1.262)       0.220      0.682(0.356-1.306)      0.248

  **Histology**                                                                                                                                                           

  Epithelial neoplasms                  26303          3158            67                                     Reference                           Reference               

  Gonadal neoplasms                     1297           40              2                                      0.744(0.156-3.540)       0.710      2.052(0.333-12.655)     0.439

  Others                                1071           145             3                                      0.762(0.201-2.886)       0.689      1.280(0.345-4.754)      0.712

  Unknown                               841            203             17                                     2.406(1.226-4.725)       0.016      2.568(1.246-5.293)      0.011

  **Surgery**                                                                                                                                                             

  U/BSO                                 12146          506             14                                     Reference                           Reference               

  Cytoreductive                         10360          1078            9                                      0.648(0.253-1.659)       0.368      0.500(0.175-1.428)      0.195

  Others                                505            76              0                                      0.000(0.000-NA)          0.993      0.000(0.000-NA)         0.997

  No                                    6501           1886            66                                     4.047(1.702 -9.624)      0.002      1.766(0.708-4.404)      0.222

  **Radiotherapy**                                                                                                                                                        

  No                                    29160          117             52                                     Reference                           Reference               

  Yes                                   352            3429            37                                     32.268 (15.423-67.508)   \<0.0001   27.036(12.397-58.963)   \<0.0001

  **Chemotherapy**                                                                                                                                                        

  No                                    9080           2421            48                                     Reference                           Reference               

  Yes                                   20432          1125            41                                     0.503(0.287-0.881)       0.016      0.432(0.236-0.791)      0.006

  **Radiation Sequence with surgery**                                                                                                                                     

  RBS                                   15             7               1                                      Reference                           Reference               

  RAS                                   235            48              17                                     2.496(0.259-24.077)      0.429      1.576(0.141-17.601)     0.712

  RBAS                                  1              1               0                                      0.000(0.000-NA)          1.000      0.000(0.000-NA)         1.000

  Others                                29261          3490            71                                     0.564(0.057-5.593)       0.625      0.994(0.089-11.057)     0.996

  **Bone Met**                                                                                                                                                            

  No                                    29160          310             61                                     Reference                           Reference               

  Yes                                   310            3214            24                                     5.095(2.737-9.488)       \<0.0001   0.706(0.350-1.424)      0.331

  Unknown                               42             22              4                                      7.271(1.811-29.190)      0.005      9.748(2.073-45.845)     0.004

  **Liver Met**                                                                                                                                                           

  No                                    27249          2120            62                                     Reference                           Reference               

  Yes                                   2120           1386            21                                     1.072(0.581-1.977)       0.824      0.144(0.073-0.281)      \<0.0001

  Unknown                               143            40              6                                      5.266(1.706-16.250)      0.004      3.836(1.104-13.323)     0.034

  **Lung Met**                                                                                                                                                            

  No                                    27538          1773            49                                     Reference                           Reference               

  Yes                                   1773           1717            37                                     5.328(3.124-9.085)       \<0.0001   0.339(0.178-0.643)      0.001

  Unknown                               201            56              3                                      1.627(0.369-7.176)       0.521      0.700(0.110-4.464)      0.706

  **CA125**                                                                                                                                                               

  Normal                                2654           78              4                                      Reference                           Reference               

  Elevated                              20241          2726            49                                     1.437(0.439-4.712)       0.549      0.957(0.251-3.647)      0.949

  Unknown                               6617           742             36                                     2.234(0.674-7.400)       0.188      1.507(0.390-5.823)      0.552

  **Insurance situation**                                                                                                                                                 

  No                                    1096           3332            7                                      Reference                           Reference               

  Yes                                   27927          154             77                                     0.506(0.201-1.274)       0.148      0.674(0.250-1.816)      0.436

  Unknown                               489            60              5                                      1.751(0.473-6.484)       0.402      1.721(0.379-7.817)      0.482
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations:

OR: odds ratio; CI: confidence interval.

###### 

Multivariate Cox Regression for the Ovary Cancer Patients with Brain Metastases

  Variables                 Patients, No.   All-Cause Mortality (model 1)   All-Cause Mortality (model 2)                                 
  ------------------------- --------------- ------------------------------- ------------------------------- ------- --------------------- ----------
  **Marital status**                                                                                                                      
  Married                   14188           35                              Reference                               Reference             
  Single                    6565            22                              0.679(0.351-1.313)              0.249   0.643(0.327-1.264)    0.200
  Divorced                  2990            8                               2.688(1.102-6.560)              0.030   2.672(1.027-6.953)    0.044
  Widowed                   4424            17                              0.710(0.355-1.419)              0.332   0.659 (0.324-1.341)   0.250
  Unknown                   1345            7                               0.515(0.185-1.429)              0.202   0.485(0.170-1.384)    0.176
  **Histology**                                                                                                                           
  Epithelial neoplasms      26303           67                              Reference                               Reference             
  Gonadal neoplasms         1297            2                               0.215(0.028-1.670)              0.142   0.215(0.028-1.675)    0.142
  Others                    1071            3                               1.183(0.144-9.737)              0.876   0.998(0.105-9.486)    0.999
  Unknown                   841             17                              0.921(0.480-1.766)              0.804   0.906(0.465-1.767)    0.906
  **Treatment**                                                                                                                           
  Others                    3371            37                              NA                              NA      Reference             NA
  CSR                       213             13                              NA                              NA      0.096(0.030-0.308)    \<0.0001
  RS                        24              3                               NA                              NA      0.283(0.060-1.342)    0.112
  SC                        17127           5                               NA                              NA      0.081 (0.021-0.312)   \<0.0001
  RC                        77              15                              NA                              NA      0.260(0.115-0.587)    0.001
  R                         38              6                               NA                              NA      1.015(0.357-2.886)    0.978
  S                         5647            2                               NA                              NA      0.207 (0.040-1.086)   0.063
  C                         3015            8                               NA                              NA      0.428(0.167-1.101)    0.078
  **Surgery**                                                                                                                             
  U/BSO                     12146           14                              Reference                               NA                    NA
  Cytoreductive             10360           9                               1.042(0.317-3.421)              0.946   NA                    NA
  Others                    505             0                               NA                              NA      NA                    NA
  No                        6501            66                              3.712(1.519-9.075)              0.004   NA                    NA
  **Radiotherapy**                                                                                                  NA                    NA
  No                        29160           52                              Reference                               NA                    NA
  Yes                       352             37                              0.893(0.481 -1.657)             0.720   NA                    NA
  **Chemotherapy**                                                                                                                        
  No                        9080            48                              Reference                               NA                    NA
  Yes                       20432           41                              0.341(0.169-0.687)              0.003   NA                    NA
  **Insurance situation**                                                                                                                 
  No                        1096            7                               Reference                               Reference             
  Yes                       27927           77                              0.776(0.315-1.912)              0.582   0.754(0.281-2.020)    0.574
  Unknown                   489             5                               0.965(0.255-3.655)              0.958   0.984 (0.242-4.006)   0.984

Abbreviations:

CI: confidence interval.

###### 

Baseline Characteristics of Patients for Ovarian Cancer Patients Diagnosed with and without Brain Metastases before and after PSM

  Variables                             Before matching   After matching                                             
  ------------------------------------- ----------------- ---------------- --------- --------------- --------------- -------
  **Age (years)**                                                          0.072                                     0.884
  Median (SD)                           61.26 (15.20)     64.16 (13.81)              63.81 (17.83)   64.16 (13.81)   
  **Marital status**                                                       0.295                                     0.554
  Married                               14153 (48.1)      35 (39.3)                  35 (39.3)       35 (39.3)       
  Single                                6542 (22.2)       22 (24.7)                  24 (27.0)       22 (24.7)       
  Divorced                              2982 (10.1)       8 (9.0)                    5 (5.6)         8 (9.0)         
  Widowed                               4408 (15.0)       17 (19.1)                  22 (24.7)       17 (19.1)       
  Unknown                               1338 (4.5)        7 (7.9)                    3 (3.4)         7 (7.9)         
  **Race**                                                                 0.058                                     0.826
  White                                 23722 (80.6)      70 (78.7)                  73 (82.0)       70 (78.7)       
  Black                                 2680 (9.1)        12 (13.5)                  12 (13.5)       12 (13.5)       
  Others                                2847 (9.7)        5 (5.6)                    3 (3.4)         5 (5.6)         
  Unknown                               174 (0.6)         2 (2.2)                    1 (1.1)         2 (2.2)         
  **Origin recode**                                                        0.766                                     0.826
  None-hispanic                         25298 (86.0)      78 (87.6)                  76 (85.4)       78 (87.6)       
  **Laterality**                                                           \<0.001                                   0.405
  Unilateral                            15409 (52.4)      32 (36.0)                  30 (33.7)       32 (36.0)       
  Bilateral                             9339 (31.7)       23 (25.8)                  17 (19.1)       23 (25.8)       
  Unknown                               4675 (15.9)       34 (38.2)                  42 (47.2)       34 (38.2)       
  **T staging**                                                            \<0.001                                   0.592
  T1                                    7800 (26.5)       11 (12.4)                  7 (7.9)         11 (12.4)       
  T2                                    3715 (12.6)       9 (10.1)                   11 (12.4)       9 (10.1)        
  T3                                    15058 (51.2)      26 (29.2)                  32 (36.0)       26 (29.2)       
  Unknown                               2850 (9.7)        43 (48.3)                  39 (43.8)       43 (48.3)       
  **N staging**                                                            \<0.001                                   0.849
  N0                                    20201 (68.7)      45 (50.6)                  48 (53.9)       45 (50.6)       
  N1                                    6181 (21.0)       21 (23.6)                  18 (20.2)       21 (23.6)       
  Unknown                               3041 (10.3)       23 (25.8)                  23 (25.8)       23 (25.8)       
  **Histology**                                                            \<0.001                                   0.849
  Epithelial neoplasms                  26236 (89.2)      67 (75.3)                  60 (67.4)       67 (75.3)       
  Gonadal neoplasms                     1295 (4.4)        2 (2.2)                    4 (4.5)         2 (2.2)         
  Others                                1068 (3.6)        3 (3.4)                    10 (11.2)       3 (3.4)         
  Unknown                               824 (2.8)         17 (19.1)                  15 (16.9)       17 (19.1)       
  **Surgery**                                                              \<0.001                                   0.176
  U/BSO                                 12132 (41.2)      14 (15.7)                  10 (11.2)       14 (15.7)       
  Cytoreductive                         10351 (35.2)      9 (10.1)                   13 (14.6)       9 (10.1)        
  Others                                505 (1.7)         0 (0.0)                    2 (2.2)         0 (0.0)         
  No                                    6435 (21.9)       66 (74.2)                  64 (71.9)       66 (74.2)       
  **Radiotherapy**                                                                                                   1.000
                                        315 (1.1)         37 (41.6)        \<0.001   37 (41.6)       37 (41.6)       
  **Chemotherapy**                                                                                                   0.653
                                        20391 (69.3)      41 (46.1)        \<0.001   45 (50.6)       41 (46.1)       
  **Radiation Sequence with surgery**                                      \<0.001                                   0.559
  RBS                                   14 (0.0)          1 (1.1)                    1 (1.1)         1 (1.1)         
  RAS                                   218 (0.7)         17 (19.1)                  23 (25.8)       17 (19.1)       
  RBAS                                  1 (0.0)           0                          0               0               
  Others                                29190 (99.2)      71 (79.8)                  65 (73.0)       71 (79.8)       
  **Treatment**                                                            \<0.001                                   0.469
  CSR                                   200 (0.7)         13 (14.6)                  18 (20.2)       13 (14.6)       
  RS                                    21 (0.1)          3 (3.4)                    2 (2.2)         3 (3.4)         
  SC                                    17122 (58.2)      5 (5.6)                    1 (1.1)         5 (5.6)         
  RC                                    62 (0.2)          15 (16.9)                  12 (13.5)       15 (16.9)       
  R                                     32 (0.1)          6 (6.7)                    5 (5.6)         6 (6.7)         
  S                                     5645 (19.2)       2 (2.2)                    4 (4.5)         2 (2.2)         
  C                                     3007 (10.2)       8 (9.0)                    14 (15.7)       8 (9.0)         
  Others                                3334 (11.3)       37 (41.6)                  33 (37.1)       37 (41.6)       
  **Bone Met**                                                             \<0.001                                   0.186
  No                                    29099 (98.9)      61 (68.5)                  70 (78.7)       61 (68.5)       
  Yes                                   286 (1.0)         24 (27.0)                  14 (15.7)       24 (27.0)       
  Unknown                               38 (0.1)          4 (4.5)                    5 (5.6)         4 (4.5)         
  **Liver Met**                                                            \<0.001                                   0.781
  No                                    27187 (92.4)      62 (69.7)                  65 (73.0)       62 (69.7)       
  Yes                                   2099 (7.1)        21 (23.6)                  20 (22.5)       21 (23.6)       
  Unknown                               137 (0.5)         6 (6.7)                    4 (4.5)         6 (6.7)         
  **Lung Met**                                                             \<0.001                                   0.298
  No                                    27489 (93.4)      49 (55.1)                  52 (58.4)       49 (55.1)       
  Yes                                   1736 (5.9)        37 (41.6)                  30 (33.7)       37 (41.6)       
  Unknown                               198 (0.7)         3 (3.4)                    7 (7.9)         3 (3.4)         
  **CA125**                                                                \<0.001                                   0.127
  Normal                                2650 (9.0)        4 (4.5)                    0 (0.0)         4 (4.5)         
  Elevated                              20192 (68.6)      49 (55.1)                  50 (56.2)       49 (55.1)       
  Unknown                               6581 (22.4)       36 (40.4)                  39 (43.8)       36 (40.4)       
  **Insurance situation**                                                  0.001                                     0.167
  No                                    1089 (3.7)        7 (7.9)                    2 (2.2)         7 (7.9)         
  Yes                                   27850 (94.7)      77 (86.5)                  84 (94.4)       77 (86.5)       
  Unknown                               484 (1.6)         5 (5.6)                    3 (3.4)         5 (5.6)         
  **Residence type**                                                       0.905                                     0.819
  Rural                                 481 (1.6)         1 (1.1)                    2 (2.2)         1 (1.1)         
  Urban                                 3364 (11.4)       12 (13.5)                  13 (14.6)       12 (13.5)       
  Metropolitan                          25554 (86.9)      76 (85.4)                  74 (83.1)       76 (85.4)       
  Unknown                               24 (0.1)          0 (0.0)                    0 (0.0)         0 (0.0)         

Abbreviations:

PSM: Propensity Score Matching; SD: Standard Deviation

###### 

Univariate and multivariate Cox Regression for the Brain Metastases of Ovary Cancer after PSM.

  Variables                             Univariate                  Multivariate in model 1   Multivariate in model 2                                                        
  ------------------------------------- --------------------------- ------------------------- ------------------------- ---------- --------------------- ---------- -- -- -- --
  **Age (years)**                                                                                                                                                            
  18-58                                 Reference                                             Reference                            Reference                                 
  ≥59                                   1.575(1.086-2.283)          0.017                     0.719 (0.418-1.237)       0.233      0.752(0.435-1.298)    0.306               
  **Marital status**                                                                                                                                                         
  Married                               Reference                                             Reference                            Reference                                 
  Single                                0.762(0.470-1.233)          0.268                     0.599(0.344-1.043)        0.070      0.548(0.317-0.948)    0.031               
  Divorced                              2.163(1.201-3.894)          0.010                     1.977(0.977-4.003)        0.058      1.882(0.890-3.981)    0.098               
  Widowed                               1.665(1.081-2.563)          0.021                     1.073(0.629-1.829)        0.797      1.002(0.583-1.723)    0.994               
  Unknown                               0.976(0.476-1.999)          0.946                     0.567(0.238-1.347)        0.199      0.532(0.220-1.288)    0.162               
  **Race**                                                                                                                                                                   
  White                                 Reference                                             NA                        NA         NA                    NA                  
  Black                                 0.829(0.513-1.340)          0.443                     NA                        NA         NA                    NA                  
  Others                                1.470(0.766-2.820)          0.247                     NA                        NA         NA                    NA                  
  Unknown                               0.466(0.065-3.348)          0.448                     NA                        NA         NA                    NA                  
  **Origin recode**                                                                                                                                                          
  Hispanic                              Reference                                             Reference                            Reference             NA                  
  Non-hispanic                          1.535(0.805-2.928)          0.193                     0.798(0.369-1.727)        0.298      0.923(0.428-1.990)    0.837               
  **Laterality**                                                                                                                                                             
  Unilateral                            Reference                                             Reference                            Reference             NA                  
  Bilateral                             0.777(0.472-1.278)          0.320                     0.694(0.379-1.270)        0.236      0.743(0.401-1.378)    0.346               
  Unknown                               1.153(0.788-1.687)          0.463                     1.119(0.679-1.846)        0.659      1.112(0.673-1.837)    0.678               
  **Tumor staging**                                                                                                                                                          
  I                                     Reference                                             NA                        NA         NA                    NA                  
  II                                    0.904(0.000-2.159E67)       0.999                     NA                        NA         NA                    NA                  
  III                                   1856.939(0.000-2.6481E61)   0.912                     NA                        NA         NA                    NA                  
  IV                                    3401.073(0.000-4.837E+61)   0.905                     NA                        NA         NA                    NA                  
  Unknown                               1933.002(0.000-2.751E+61)   0.912                     NA                        NA         NA                    NA                  
  **T staging**                                                                                                                                                              
  T1                                    Reference                                             Reference                 NA         Reference             NA                  
  T2                                    0.759(0.355-1.621)          0.477                     0.794(0.335-1.882)        0.600      0.872(0.365-2.082)    0.757               
  T3                                    0.890(0.476-1.662)          0.714                     0.921(0.430-1.973)        0.832      1.007(0.481-2.108)    0.985               
  Unknown                               1.047(0.576-1.902)          0.880                     0.687(0.315-1.499)        0.346      0.697(0.324-1.503)    0.358               
  **N staging**                                                                                                                                                              
  N0                                    Reference                                             Reference                 NA         Reference             NA                  
  N1                                    1.203(0.779-1.856)          0.405                     1.165(0.690-1.965)        0.568      1.183(0.697-2.011)    0.533               
  Unknown                               1.473(0.975-2.225)          0.066                     1.013(0.609-1.685)        0.960      1.006(0.601-1.684)    0.981               
  **Histology**                                                                                                                                                              
  Epithelial neoplasms                  Reference                                             Reference                            Reference             NA                  
  Gonadal neoplasms                     0.324(0.045-2.323)          0.262                     0.192(0.024-1.508)        0.117      0.176(0.022-1.392)    0.100               
  Others                                0.696(0.323-1.499)          0.355                     0.793(0.302-2.079)        0.637      0.976(0.376-2.535)    0.960               
  Unknown                               1.293(0.824-2.030)          0.264                     0.592(0.336-1.043)        0.070      0.606(0.342-1.072)    0.085               
  **Treatment**                                                                                                                                                              
  Others                                Reference                                             NA                        NA         Reference                                 
  CSR                                   0.209(0.112-0.390)          \<0.0001                  NA                        NA         0.104(0.045-0.236)    \<0.0001            
  RS                                    0.555(0.136-2.275)          0.414                     NA                        NA         0.350 (0.069-1.783)   0.206               
  SC                                    0.224(0.081-0.620)          0.004                     NA                        NA         0.061(0.018-0.212)    \<0.0001            
  RC                                    0.357(0.215-0.595)          \<0.0001                  NA                        NA         0.231(0.124-0.429)    \<0.0001            
  R                                     0.863(0.443-1.683)          0.666                     NA                        NA         0.710(0.307-1.641)    0.423               
  S                                     0.340(0.136-0.847)          0.021                     NA                        NA         0.231(0.070-0.763)    0.016               
  C                                     0.502(0.285-0.884)          0.017                     NA                        NA         0.310(0.158-0.608)    0.001               
  **Surgery**                                                                                                                                                                
  U/BSO                                 Reference                                             Reference                            NA                    NA                  
  Cytoreductive                         1.117(0.483-2.582)          0.797                     1.120 (0.427-2.938)       0.818      NA                    NA                  
  Others                                0.000(0.000- 4.8509E168)    0.959                     0.000(0.000-7.797E+183)   0.961      NA                    NA                  
  No                                    2.743(1.564-4.810)          \<0.0001                  3.141(1.433-6.886)        0.004      NA                    NA                  
  **Radiotherapy**                                                                                                                                                           
  No                                    Reference                                             Reference                            NA                    NA                  
  Yes                                   0.499(0.347-0.717)          \<0.0001                  0.817(0.462-1.442)        0.485      NA                    NA                  
  **Chemotherapy**                                                                                                                                                           
  No                                    Reference                                             Reference                            NA                    NA                  
  Yes                                   0.3720.260-0.531()          \<0.0001                  0.298(0.180-0.495)        \<0.0001   NA                    NA                  
  **Radiation Sequence with surgery**                                                                                                                                        
  Others                                Reference                                             Reference                            NA                    NA                  
  RBS                                   0.365(0.090-1.481)          0.158                     1.283(0.247-6.660)        0.767      NA                    NA                  
  RAS                                   NA                          NA                        NA                        NA         NA                    NA                  
  RBAS                                  0.417(0.250-0.697)          0.001                     1.151(0.536-2.473)        0.718      NA                    NA                  
  **Brain Met**                                                                                                                                                              
  No                                    Reference                                             Reference                            Reference                                 
  Yes                                   1.327(0.943-1.866)          0.104                     1.600(1.042-2.458)        0.032      1.653(1.076-2.541)    0.022               
  **Bone Met**                                                                                                                                                               
  No                                    Reference                                             Reference                            Reference                                 
  Yes                                   1.186(0.780-1.805)          0.425                     0.951 (0.554 -1.630)      0.854      1.040(0.596-1.814)    0.891               
  Unknown                               1.877(0.999-3.528)          0.050                     0.977(0.307-3.112)        0.969      0.974(0.297-3.193)    0.965               
  **Liver Met**                                                                                                                                                              
  No                                    Reference                                             Reference                            Reference                                 
  Yes                                   1.756(1.187-2.598)          0.005                     1.899(1.119-3.223)        0.018      1.941(1.140-3.303)    0.015               
  Unknown                               1.995(0.999-3.987)          0.050                     1.506(0.535-4.236)        0.438      1.584(0.556-4.508)    0.389               
  **Lung Met**                                                                                                                                                               
  No                                    Reference                                             Reference                            Reference                                 
  Yes                                   1.834(1.274-2.641)          0.001                     1.374(0.826-2.284)        0.221      1.305(0.785-2.169)    0.305               
  Unknown                               1.949(0.934-4.068)          0.075                     1.500(0.455-4.941)        0.505      1.436(0.438-4.712)    0.550               
  **CA125**                                                                                                                                                                  
  Normal                                Reference                                             Reference                 NA         Reference             NA                  
  Elevated                              2.338(0.850-6.428)          0.100                     1.543(0.502-4.747)        0.449      1.502(0.488-4.621)    0.478               
  Unknown                               2.063(0.747-5.702)          0.163                     1.398(0.457-4.275)        1.398      1.387(0.452-4.259)    0.567               
  **Insurance situation**                                                                                                                                                    
  No                                    Reference                                             Reference                            Reference                                 
  Yes                                   0.491(0.274-0.878)          0.017                     0.701 (0.323-1.522)       0.369      0.704(0.324-1.531)    0.376               
  Unknown                               0.644(0.210-1.980)          0.443                     0.897(0.234-3.446)        0.875      0.938(0.244-3.607)    0.926               
  **Residence type**                                                                                                                                                         
  Rural                                 Reference                                             Reference                 NA         Reference             NA                  
  Urban                                 0.599(0.177-2.023)          0.409                     0.956(0.202-4.525)        0.955      0.892(0.182-4.373)    0.888               
  Metropolitan                          0.428(0.135-1.359)          0.150                     0.587(0.129-2.677)        0.491      0.535(0.112-2.547)    0.432               
  Unknown                               NA                          NA                        NA                        NA         NA                    NA                  
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